DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Predicting Gastric Neoplasia in Patients with High-risk Endoscopic Features

Not yet recruiting

Conditions: Gastric Neoplasia

First Posted Date: 2025-03-03

Last Posted Date: 2025-03-03

Lead Sponsor: Fudan University

Target Recruit Count: 2700

Registration Number: NCT06853509

Locations: 🇨🇳
Huadong hospital affiliated to Fudan university, Shanghai, Shanghai, China

HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Advanced Triple Negative Breast Cancer

Interventions: Drug: Camrelizumab
Drug: SKB264
Drug: Nab-paclitaxel
Drug: Lenvatinib

First Posted Date: 2025-02-27

Last Posted Date: 2025-02-27

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT06849492

Locations: 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Microsatellite Stable Metastatic Colorectal Cancer

Interventions: Radiation: Ultra-fractionated radiation therapy
Drug: Sintilimab
Drug: Standard systemic therapy

First Posted Date: 2025-02-24

Last Posted Date: 2025-02-24

Lead Sponsor: Fudan University

Target Recruit Count: 116

Registration Number: NCT06841159

Locations: 🇨🇳
Fudan University, Shanghai, China

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2025-02-21

Last Posted Date: 2025-02-21

Lead Sponsor: Fudan University

Target Recruit Count: 46

Registration Number: NCT06840665

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma HNSCC

Interventions: Drug: Pembrolizumab
Drug: Ivonescimab
Procedure: Surgery
Radiation: Adjuvant radiotherapy

First Posted Date: 2025-02-07

Last Posted Date: 2025-02-07

Lead Sponsor: Fudan University

Target Recruit Count: 80

Registration Number: NCT06814067

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence

Phase 2

Recruiting

Conditions: Hepato Cellular Carcinoma (HCC)

Interventions: Drug: HAIC combined with sintilimab and donafenib
Drug: Sintilimab and Donafenib
Procedure: Surgery

First Posted Date: 2025-02-06

Last Posted Date: 2025-02-06

Lead Sponsor: Fudan University

Target Recruit Count: 165

Registration Number: NCT06812039

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
TianJin Medical University Cancer Institute & Hospital, TianJin, Tianjin, China

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

Not yet recruiting

Conditions: TNBC - Triple-Negative Breast Cancer

First Posted Date: 2025-01-29

Last Posted Date: 2025-01-29

Lead Sponsor: Fudan University

Target Recruit Count: 300

Registration Number: NCT06798506

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

Phase 3

Not yet recruiting

Conditions: Triple-negative Breast Cancer

Interventions: Drug: Docetaxel plus cyclophosphamide
Drug: Epirubicin, cyclophosphamide plus paclitaxel

First Posted Date: 2025-01-28

Last Posted Date: 2025-01-28

Lead Sponsor: Fudan University

Target Recruit Count: 1462

Registration Number: NCT06795503

Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

Phase 2

Not yet recruiting

Conditions: Metastatic Breast Cancer
Breast Cancer

Interventions: Drug: Trastuzumab deruxtecan (T-DXd)

First Posted Date: 2025-01-28

Last Posted Date: 2025-01-28

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT06797622

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

Phase 2

Recruiting

Conditions: Triple-Negative Breast Cancer (TNBC)
Brain Metastases

Interventions: Drug: Ivonescimab Combined With TROP2 ADC

First Posted Date: 2025-01-27

Last Posted Date: 2025-01-27

Lead Sponsor: Fudan University

Target Recruit Count: 39

Registration Number: NCT06793332

Locations: 🇨🇳
Fudan University Shanghai Cancer center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy